Physician profile
Jisha Thomas
NPI 1255076824
$2,114.91
in general payments reported to CMS, 2019-2025
20 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what 89% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $54.17 · 2023: $425 · 2024: $533 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,060.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $613.82 | 2023-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $382.79 | 2023-2025 | Omnipod |
| Corcept Therapeutics | $247.63 | 2023-2025 | Korlym |
| Neurocrine Biosciences, INC. | $216.93 | 2025 | |
| Beta Bionics, INC. | $130.83 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ascendis Pharma Endocrinology INC | $128.84 | 2025 | Yorvipath |
| Novartis Pharmaceuticals Corporation | $71.52 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $59.17 | 2024-2025 | |
| Embecta Corp. | $38.76 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Amgen INC. | $30.96 | 2023 | |
| Tandem Diabetes Care, INC. | $24.02 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $22.87 | 2025 | |
| Janssen Pharmaceuticals, INC | $22.10 | 2022 | |
| Ascensia Diabetes Care US INC. | $22.05 | 2025 | |
| Lilly USA, LLC | $21.60 | 2024 | Zepbound, Mounjaro |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $20.25 | 2024 | Isturisa, Signifor Lar |
| Novo Nordisk INC | $17.04 | 2025 | Ozempic |
| Opko Pharmaceuticals, LLC | $15.34 | 2024 | Rayaldee |
| Rhythm Pharmaceuticals, INC. | $15.34 | 2025 | Imcivree |
| Kiniksa Pharmaceuticals, LTD. | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jisha Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.